Personalized follow-up treatment after surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial is looking at whether giving extra treatment after surgery for stomach cancer can help lower the chance of it coming back. It is for people who had a specific kind of chemotherapy and immunotherapy before surgery and then had their stomach removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had surgery to remove your stomach cancer (gastrectomy), and the surgeon was able to remove all visible cancer (R0 resection).
- You must have received a specific combination of chemotherapy and immunotherapy before your surgery.
- Your cancer must have been completely removed and you must show no signs of it spreading or coming back.
- You must be in good overall health, with a performance status of 0 or 1, meaning you can carry out your daily activities.
- You must have normal organ function, which will be checked with blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
This trial compares two approaches after surgery for early-stage stomach or GEJ cancer: close monitoring (follow-up) vs. adjuvant chemotherapy (chemo given after surgery). It aims to see if follow-up alone is as good as chemo for patients with this stage, potentially avoiding chemo side effects.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This study looks at using a blood test that finds tiny bits of cancer DNA to decide if you need extra chemotherapy after surgery. It aims to make treatment more personalized and reduce side effects for people with locally advanced stomach cancer.
This trial tests an early treatment plan after stomach cancer surgery. It is for people who completed chemotherapy before surgery without serious side effects and had a short hospital stay.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.